Milestone |126 Papers, One Clear Trend: SeekGene's Single-Cell Research Momentum, January–August 2026
Release date : Sep 08,2026
Classification : Blog
126 papers, one clear trend
Eight months into 2026, SeekGene's single-cell and spatial multi-omics platforms keep showing up in the papers that matter most — here's what the data says.
From January to August 2026, SeekGene supported customers in publishing 126 project papers across 95 journals, with a cumulative impact factor of 1,582.6 and an average IF of 12.6 per paper. Over half of these papers — 50.8% — appeared in journals with an impact factor of 10 or higher. Four papers landed in CNS flagship journals: three in Nature and one in Cell.
|
|
| |||
|
|
|
Impact factor distribution
The share of high-impact publications continues to climb, with 31 papers — 24.6% of the total — now reaching an impact factor of 15 or higher.
| IF range | Papers | Share |
|---|---|---|
| IF ≥ 30 | 9 | 7.1% |
| IF 20–30 | 6 | 4.8% |
| IF 15–20 | 16 | 12.7% |
| IF 10–15 | 33 | 26.2% |
| IF 5–10 | 34 | 27.0% |
| IF < 5 | 28 | 22.2% |
Innovative technologies vs. conventional technologies
Papers built on scFAST-seq full-length transcriptomics, FFPE transcriptomics, SeekSpace™ spatial transcriptomics, and single-cell ATAC+RNA / methylation+RNA assays — all run on the SeekOne™ DD platform — made up just 12% of output but punched well above their weight.
| Metric | Innovative tech | Conventional tech |
|---|---|---|
| Number of papers | 15 (11.9%) | 111 (88.1%) |
| Cumulative IF | 231.7 (14.6%) | 1,350.9 |
| Average IF | 15.4 | 12.2 |
| Median IF | 11.7 | 8.7 |
| Share with IF ≥ 10 | 60% (9/15) | 50% (55/111) |
| Share with IF ≥ 15 | 33% (5/15) | 23% (26/111) |
| Share with IF ≥ 20 | 13% (2/15) | 14% (15/111) |
| Papers with IF ≥ 30 | 2 (13%) | 7 (6%) |
| Highest IF | 56.1 (Nature) | 56.1 (Nature) |
| CNS flagship papers | Nature ×1 | Nature ×2, Cell ×1 |
Average IF for the innovative-technology group ran 26% higher than for conventional-technology papers, and median IF ran 34% higher — a clear "fewer papers, higher quality" pattern.
Top-tier journal highlights
From January to August 2026, SeekGene supported a steady stream of publications in CNS flagship and leading field journals.
| Journal | IF | Papers | Research focus |
|---|---|---|---|
| Nature | 56.1 | 3 | Vertebrate brain cell-type evolution; T-cell exhaustion; diet–T-cell ferroptosis and immunity |
| European Heart Journal | 45.3 | 1 | Fulminant myocarditis |
| Cell | 45.1 | 1 | B-cell–liver metabolic axis and exercise capacity |
| Circulation | 41.3 | 1 | Adverse post-ischemic cardiac remodeling |
| Journal of Hepatology | 40.1 | 1 | Tertiary lymphoid structures and anti-tumor immunity in hepatocellular carcinoma |
| Cell Metabolism | 37.0 | 1 | Metabolic reprogramming and immune evasion in hepatocellular carcinoma |
| Cell Research | 31.1 | 1 | Aging-related cognitive decline |
| Nature Cancer | 28.0 | 1 | Ferroptosis and CAR-T cell efficacy |
| Nature Metabolism | 27.5 | 1 | Sex-specific CD8⁺ T-cell anti-tumor responses |
| Nature Aging | 25.0 | 1 | Aging-associated inflammation and post-chemotherapy functional recovery |
| Cellular & Molecular Immunology* | 23.9 | 2 | Type 2 airway inflammation; colitis |
| Bioactive Materials | 23.6 | 1 | Artificial platelets for deep vein thrombosis |
| Cell Stem Cell | 23.3 | 1 | Functional bridging of the optic nerve by retinal organoids |
| Nature Microbiology | 18.7 | 1 | Functional receptor for yellow fever virus |
| Nature Communications | 18.1 | 10 | Tumor microenvironment, pluripotency reprogramming, organoids, single-cell methylation methodology, and more |
| Advanced Science | 14.1 | 6 | Cancer, neuroscience, immunology, and other disease areas |
*Cellular & Molecular Immunology is a Springer Nature partner journal, not a Nature-branded sub-journal.
Research field distribution
Research spanned oncology, immunology, neuroscience, cardiovascular disease, reproduction and development, and other frontier fields — with oncology and immunology/inflammation together accounting for over 60% of output.
| Oncology / cancer | 40% | |||
| Infection / inflammation / immunology | 22% | |||
| Neuroscience / brain science | 14% | |||
| Cardiovascular | 6% | |||
| Reproduction / development / stem cells | 6% | |||
| Liver / digestive | 2% | |||
| Methodology / technology | 2% | |||
| Other (respiratory, renal, dermatology, etc.) | 8% |
Representative research areas included hepatocellular carcinoma, lung squamous cell carcinoma, triple-negative breast cancer, renal cell carcinoma, prostate cancer, colorectal cancer, leukemia, fulminant myocarditis, ischemic cardiac remodeling, Alzheimer's disease, amyotrophic lateral sclerosis, aging and cognitive decline, ulcerative colitis, type 2 airway inflammation, deep vein thrombosis, optic nerve regeneration, yellow fever virus infection, ginsenoside biosynthesis, and vertebrate brain evolution.
Nationwide collaboration network
In 2026, project-paper collaborators spanned 24 provincial-level regions across China, forming a collaboration network covering the east, south, west, north, and central regions.
|
|
Internationally, five papers in 2026 involved overseas collaborators, with partner institutions based in Australia, the Netherlands, Sweden, and Russia — reflecting the continued expansion of SeekGene's international service footprint.
Platform empowerment
SeekGene's full-chain product matrix continues to deliver a one-stop single-cell solution for research customers, spanning sample processing through data analysis. Among 2026 papers, 92% — 116 papers — used the SeekOne™ DD single-cell sequencing platform, and 11 papers used the SeekSoul Online cloud platform for data mining.
Cross-species research: from the deep sea to medicinal fields
Research subjects in 2026 spanned humans, model organisms, agricultural animals, and plants — showcasing the broad applicability of single-cell and spatial multi-omics across life science.
|
|
|
| Spotlight. Non-human research published in 2026 spanned a wide range of species — an atlas of the amphioxus endostyle (Science Advances, on the evolutionary origin of vertebrate pharyngeal organs), along with regionally distinctive agricultural and model-organism studies in yellow catfish, chicken, pig, goat, and monkey. Plant studies included ginseng (Nature Communications, identifying the ginseng embryonic epidermis as a natural high-efficiency compartment for ginsenoside biosynthesis), as well as Phoebe zhennan (golden-thread nanmu) and camphor tree — continuing to push the boundaries of the SeekGene platform's application in non-human samples. |
Multi-omics joint analysis becomes the mainstream approach
In papers published in 2026, combining single-cell sequencing with multi-omics and multi-technology approaches has become the dominant research paradigm — 24 papers applied two or more technologies jointly.
- scRNA-seq + TCR/BCR immune repertoire profiling
- Single-cell transcriptomics + spatial transcriptomics (SeekSpace™, with Visium cross-validation)
- Single-cell dual-omics: ATAC+RNA, methylation+RNA from the same cell
- Single-nucleus transcriptomics + full-length transcriptomics (capturing non-poly(A) and repetitive sequences)
- Single-cell sequencing + SeekSoul Online cloud platform deep data mining
- FFPE archival sample single-cell transcriptomics + spatial omics retrospective cohort studies
Summary & outlook
From January to August 2026, SeekGene supported partner customers in publishing 126 high-quality project papers, with a cumulative impact factor of 1,582.6 and an average IF of 12.6 per paper. Key trends this year include:
- Top-journal breakthroughs — 3 Nature and 1 Cell flagship papers; 64 papers (50.8%) with IF ≥ 10; sustained high output in CNS sub-journals and leading field journals.
- Single-cell multi-omics momentum — ATAC+RNA and methylation+RNA single-cell dual-omics assays featured in Nature and Nature Communications, extracting multi-dimensional regulatory information from the same cell.
- Fewer, higher-impact innovative-technology papers — average IF of 15.4, 26% higher than conventional-technology papers, with roughly double the hit rate for IF ≥ 30 top journals.
- Spatial omics in practice — SeekSpace™ spatial transcriptomics supported high-level research including a Journal of Hepatology study, restoring in-situ tissue landscapes at physical single-cell resolution.
- Deeper adoption of differentiated products — 5′+VDJ/TCR immune repertoire profiling, scFAST-seq full-length transcriptomics, single-nucleus, and FFPE workflows applied extensively in oncology, aging, evolution, and infectious disease research.
- Full-chain service — from tissue dissociation and sample pre-processing through SeekSoul Online cloud-based data mining, SeekGene's complete product line was deployed in depth across projects.
- International expansion — published results with overseas collaborators in Australia, the Netherlands, Sweden, and Russia, continuing to grow SeekGene's global service footprint.
- Expanding species coverage — from human disease research to amphioxus, yellow catfish, ginseng, Phoebe zhennan, and other animal and plant species, continuously extending the boundaries of single-cell technology applications.
| SeekGene remains committed to building a comprehensive single-cell multi-omics technology matrix, striving to be the platform of choice for every researcher's next discovery — driving innovation and decoding the unknowns of life through single-cell epigenomics and spatial multi-omics. |
attachment：
Hot News
Sep 08,2026
Thank You For Your Interest ！
Please fill out this form to view or download the materials you require.